Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 6/1999

01-08-1999 | ORIGINAL ARTICLE

An EGP-2/Ep-CAM-expressing transgenic rat model to evaluate antibody-mediated immunotherapy

Authors: Pamela M. J. McLaughlin, Bart-Jan Kroesen, Wim H. A. Dokter, Henk van der Molen, Martijn de Groot, Marja G.L. Brinker, Klaas Kok, Marcel H. J. Ruiters, Charles H. C. M. Buys, Lou F. M. H. de Leij

Published in: Cancer Immunology, Immunotherapy | Issue 6/1999

Login to get access
Metadata
Title
An EGP-2/Ep-CAM-expressing transgenic rat model to evaluate antibody-mediated immunotherapy
Authors
Pamela M. J. McLaughlin
Bart-Jan Kroesen
Wim H. A. Dokter
Henk van der Molen
Martijn de Groot
Marja G.L. Brinker
Klaas Kok
Marcel H. J. Ruiters
Charles H. C. M. Buys
Lou F. M. H. de Leij
Publication date
01-08-1999
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 6/1999
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s002620050579

Other articles of this Issue 6/1999

Cancer Immunology, Immunotherapy 6/1999 Go to the issue

ORIGINAL ARTICLE

Synergistic antitumor effects of interleukin-12 gene transfer and systemic administration of interleukin-18 in a mouse bladder cancer model

REVIEW

Generating a T cell tumor-specific immune response in vivo: can flt3-ligand-generated dendritic cells tip the balance?

SHORT COMMUNICATION

Generation of protective immunity against an immunogenic carcinoma requires CD40/CD40L and B7/CD28 interactions but not CD4+ T cells

ORIGINAL PAPER

The induction of distinct cytokine cascades correlates with different effects of granulocyte-colony stimulating factor and granulocyte/macrophage-colony-stimulating factor on the lymphocyte compartment in the course of high-dose chemotherapy for breast cancer

ORIGINAL ARTICLE

The role of possible risk factors for acute and late renal dysfunction after high-dose interleukin-2, interferon α and lymphokine-activated killer cells

ORIGINAL ARTICLE

Gene therapy with cytokine-transfected xenogenic cells (Vero-IL-2) in patients with metastatic solid tumors: mechanism(s) of elimination of the transgene-carrying cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits